LOCOREGIONAL THERAPY
These treatments go by a variety of names but they all have one thing in common; they are guns. By this I mean they go where they are aimed. They do not treat liver cancer in multiple areas of the liver at one time nor to they treat cancer that has spread to other parts of the body.
They are extremely effective at controlling local disease with response rates well above 90%. Treatments that are available at the Liver Cancer Treatment Program with our partners include:
Yttrium-90 (Y90) radioembolization with SIR Spheres
Transarterial chemoembolization (TACE)
Percutaneous and laparoscopic ablation
SYSTEMIC THERAPY
We pioneered the use of systemic therapy for advanced hepatocellular cancer beginning in 2007 participating in early phase clinical trials of trebanib, tivantinib, sorafenib and immune therapy with pembrolizumab, nivolumab and other agents. Now we are revolutionizing the field with early intervention with systemic therapy. All forms of oral and intravenous immune therapy and chemotherapy are available as well as participation in novel clinical trials of new treatments. Treatments available at the Liver Cancer Treatment Program include:
Immune combination therapies
Tecentriq and Avastin (Atezolizumab and Bevacizumab)
Opdivo and Yervoy (Nivolumab and Ipilimumab)
Imfinzi and Imjudo (Durvalumab and Tremelimumab)
Chemotherapy
Cabometyx (Cabozantinib)
Lenvima (Lenvatinib)
Nexavar (Sorafenib)